Woodline Partners’s Ambrx Biopharma Inc AMAM Stock Holding History

Woodline Partners’s Portfolio AMAM Stock Details AMAM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-1,255,148	Closed	-$17.9M	–	671
2023 Q4	$17.9M	Buy	+1,255,148	New	+$14.3M	0.19%	161

Woodline Partners's AMAM Position: Q1 2024 in Review

Woodline Partners sold out of Ambrx Biopharma Inc (AMAM) in Q1 2024, closing a stake of 1,255,148 shares — an estimated $17.9M sold.

Woodline Partners first reported a position in AMAM in Q4 2023 and held it in 1 quarter. The position peaked at $17.9M in Q4 2023. 0 funds tracked by Wall St. Rank hold AMAM as of Q1 2024.

Woodline Partners reported no remaining Ambrx Biopharma Inc position as of Q1 2024 after selling out during the quarter.
Woodline Partners sold 1,255,148 Ambrx Biopharma Inc shares in Q1 2024, an estimated $17.9M.
Woodline Partners first reported a position in Ambrx Biopharma Inc in Q4 2023 and held it in 1 quarter.
Woodline Partners's Ambrx Biopharma Inc position peaked at $17.9M in Q4 2023.
0 funds tracked by Wall St. Rank held Ambrx Biopharma Inc as of Q1 2024.

Based on Woodline Partners's 13F filing for Q1 2024, filed 15 May 2024.